Dexa Group Library

  • Home
  • Information
  • News
  • Help
  • Librarian
  • Member Area
  • Select Language :
    Arabic Bengali Brazilian Portuguese English Espanol German Indonesian Japanese Malay Persian Russian Thai Turkish Urdu

Search by :

ALL Author Subject ISBN/ISSN Advanced Search

Last search:

{{tmpObj[k].text}}
Image of The Effect of Phaleria macrocarpa Bioactive Fraction (Proliverenol) Supplementation on Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
Bookmark Share

PRODUCT LITERATURE

The Effect of Phaleria macrocarpa Bioactive Fraction (Proliverenol) Supplementation on Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

Hasan I - Personal Name;

Liver is considered one of the most vital organs, acting as the center of metabolism of nutrients and excretion of waste products. Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of chronic liver disease. The management of NAFLD continues to evolve, and clinicians are currently faced with a variety of alternative options, both non-pharmacotherapeutic and pharmacotherapy, to avoid more severe liver disease. Phaleria macrocarpa (Scheff.) Boerl., namely, mahkota dewa in Indonesia, has been used empirically to treat cancer, allergy, and diabetes mellitus. Proliverenol is a proprietary bioactive fraction derived from the dried fruit of Phaleria macrocarpa (Scheff.) Boerl. Proliverenol was reported to have hepatoprotective, anti-inflammatory, antioxidant, and antifibrotic effects. The study found that Proliverenol bioactive fraction, at a dosage of 1000 mg twice daily for at least 4 weeks of treatment, is effective in improving liver damage with a good safety profile.


Availability
#
Location name is not set Location name is not set
Veprolin-001
Available
Detail Information
Series Title
-
Call Number
-
Publisher
: .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
LITERATURE
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Phaleria macrocarpa
Mahkota Dewa
Proliverenol
Non-alcoholic fatty liver disease
Veprolin
Specific Detail Info
Medicinus 2025;38(7):7-20
Statement of Responsibility
-
Other version/related

No other version available

File Attachment
  • Read Here
Comments

You must be logged in to post a comment

Dexa Group Library
  • Information
  • Services
  • Librarian
  • Member Area

About Us

This digital catalog is dedicated to all members of DEXAN as part of our ongoing effort to provide practical, effective, efficient, up-to-date, and comprehensive information services that can be accessed anytime and anywhere.We have developed this website as a medium for information sharing and user interaction. We are committed to continuous innovation in order to become a reliable source of information that meets the evolving needs of DEXAN. Our mission includes supporting literacy culture enhancement programs and improving service quality.Inspired by the concept of The Dynamic Library, we are constantly evolving to optimize our role in supporting and facilitating research, education, preservation, information, and recreation—while striving to deliver excellent service.This platform also offers a guide on how to independently access information through this digital catalog.

Search

start it by typing one or more keywords for title, author or subject

Keep SLiMS Alive Want to Contribute?

© 2026 — Senayan Developer Community

Powered by SLiMS
Select the topic you are interested in
  • Computer Science, Information & General Works
  • Philosophy & Psychology
  • Religion
  • Social Sciences
  • Language
  • Pure Science
  • Applied Sciences
  • Art & Recreation
  • Literature
  • History & Geography
Icons made by Freepik from www.flaticon.com
Advanced Search
Where do you want to share?